Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

× No keyword cloud information.

11 in total

1. No reduction in cardiovascular risk with NSAIDs-including aspirin?

Authors: John G F Cleland
Journal: Lancet Date: 2002-01-12 Impact factor: 79.321

Review 2. Rheumatology: 7. Basics of therapy.

Authors: S H Huang
Journal: CMAJ Date: 2000-08-22 Impact factor: 8.262

3. Digging for data from the COX-2 trials.

Authors: James P McCormack; Robert Rangno
Journal: CMAJ Date: 2002-06-25 Impact factor: 8.262

4. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.

Authors: Wayne A Ray; C Michael Stein; Kathi Hall; James R Daugherty; Marie R Griffin
Journal: Lancet Date: 2002-01-12 Impact factor: 79.321

5. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

Review 6. Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors: D Mukherjee; S E Nissen; E J Topol
Journal: JAMA Date: 2001 Aug 22-29 Impact factor: 56.272

7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

1. No reduction in cardiovascular risk with NSAIDs-including aspirin?

Review 2. Rheumatology: 7. Basics of therapy.

3. Digging for data from the COX-2 trials.

4. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.

5. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Review 6. Risk of cardiovascular events associated with selective COX-2 inhibitors.

7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

8. Association between naproxen use and protection against acute myocardial infarction.

9. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

10. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

Review 1. Selective COX-2 inhibitors: a health economic perspective.

2. The 2001 Canadian hypertension recommendations: take-home messages.

3. COX-2 inhibitors and type 4 error.

4. Coxib medications to be handled with care.

5. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.

Review 6. The double-edged sword of COX-2 selective NSAIDs.

7. Biological basis and clinical implications of acetylsalicylic acid resistance.